Decitabine-SAGO® for Injection 50 mg
A lyophilized cytotoxic injectable used in the treatment of hematological malignancies under specialist oncology supervision.
Description
Decitabine-SAGO® for Injection 50 mg is a sterile lyophilized cytotoxic formulation intended for intravenous administration after aseptic reconstitution. Each vial contains 50 mg of decitabine and is supplied for hospital and institutional use only. Decitabine acts as a hypomethylating agent, inhibiting DNA methylation and promoting cellular differentiation or apoptosis in malignant cells. The product is manufactured for SAGO Pharma in compliance with international quality and safety standards and is intended for controlled oncology settings.
Parturient ut id tellus vulputatre ac ultrlices a part ouriesnt sapien dignissim partu rient a a inter drum vehicula. Ornare metus laoreet tincidunt eros rolem tristique pretium malada.
Cras rhoncus vivamus luctus platea arcu laoreet selm. Curae est condenectus sed hac a parturient vestibulum.
-
Myelodysplastic syndromes (MDS)
-
Acute myeloid leukemia (AML)
-
Hematological malignancies requiring hypomethylating therapy
-
Oncology treatment protocols as directed by specialists
Reviews
There are no reviews yet.